Zerigo Health is a technology company.
Zerigo Health has raised $61.0M across 2 funding rounds.
Zerigo Health has raised $61.0M in total across 2 funding rounds.
Zerigo Health has raised $61.0M in total across 2 funding rounds.
Zerigo Health's investors include 7wire Ventures, Brand Foundry Ventures, New Leaf Venture Partners, SV Health Investors, Casey Tansey, Gordon Segal.
Zerigo Health is a San Diego-based medtech company founded in 2014 that develops portable, FDA-cleared narrowband UVB (NB-UVB) phototherapy devices and a connected care platform for treating chronic skin conditions like psoriasis, eczema, and vitiligo.[1][2][5] It serves patients seeking at-home alternatives to in-office treatments, dermatologists, employers, and health plans by solving the problem of inconvenient, frequent clinic visits and ineffective topicals through a holistic program combining hardware, a machine-learning app for personalized plans, and dedicated care guides—driving higher adherence and better outcomes while reducing healthcare costs.[2][3][4][6] The company has raised $67.25M, including a $43M Series B in 2021, and rebranded from Clarify Medical in 2020 to emphasize its comprehensive ecosystem.[1][3]
Zerigo Health was founded in 2014 by Martyn Gross, inspired by his personal struggle with psoriasis; he experienced strong results from UVB phototherapy but found thrice-weekly dermatologist visits unsustainable, prompting him to create an at-home solution without trade-offs.[5] Originally operating as Clarify Medical, the company developed a smartphone-connected NB-UVB device and rebranded to Zerigo Health in 2020 under President and CEO John Schellhorn to better reflect its focus on eczema, psoriasis, and vitiligo (deriving the name from those conditions).[3] Early traction came from FDA clearance for its clinical-grade handheld device, followed by the $43M Series B in 2021 amid rising demand for home-based care, especially during the pandemic.[1][3][4]
Zerigo rides the wave of digital health and at-home care trends, accelerated by the pandemic, where chronic conditions like psoriasis (affecting 3% globally) and eczema impact 1 in 10 people, yet clinic-based phototherapy limits access amid rising biologics costs.[3][4][5] Timing aligns with payer demands for value-based care: its platform cuts premiums by favoring effective, non-systemic phototherapy over pricier therapies, while AI/app integration taps telehealth growth.[6] Market forces like 40M+ U.S. sufferers, employee wellness focus, and insurance expansion efforts amplify this; Zerigo influences dermatology by pioneering connected phototherapy, potentially standardizing home delivery and lowering systemic healthcare waste.[4][5][6]
Zerigo is poised to scale as a leader in skin health tech, expanding insurance coverage beyond U.S. self-pay to become a standard benefit, while iterating on AI personalization and global reach.[4] Trends like AI-driven care, employer-sponsored wellness, and phototherapy's edge over immunosuppressants will fuel growth, especially as data proves ROI for payers. Its influence may evolve from niche disruptor to ecosystem enabler, empowering clear skin access and redefining dermatology delivery—realizing Gross's vision of sustainable, tradeoff-free treatment for millions.[5][6]
Zerigo Health has raised $61.0M across 2 funding rounds. Most recently, it raised $43.0M Series B in October 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2021 | $43.0M Series B | 7wire Ventures, Brand Foundry Ventures, New Leaf Venture Partners, SV Health Investors, Casey Tansey, Gordon Segal | |
| Oct 1, 2019 | $18.0M Series A | 7wire Ventures, New Leaf Venture Partners, SV Health Investors, Casey Tansey |